- Chambers HF. Short-course combination and oral therapies of Staphylococcus aureus endocarditis.
Med Clin North Am 1993; 7:69–80. - Korzeniowski O, Sande MH. The national collaborative endocarditis study group combination
antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral
drugs and in non-addicts: a prospective study. Ann Intern Med 1982; 92:619–624. - Karchmer AW. Infections of prosthetic heart valves. In: Waldvogel F, Bisno AL, eds. Infections
associated with indwelling medical devices. Washington DC: American Society for Microbiology,
2000:145–172. - Chuard C, Herrmann M, Roehner P, et al. Treatment of experimental foreign body infections caused
by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1990; 34:2312–2317. - Stryjewski ME. Use of vancomycin or first-generation cephalosporins for the treatment of
hemodialysis-dependent patients with methicillin susceptible Staphylococcus aureus bacteremia.
Clin Infect Dis 2007; 24:190–196. - Lodise TP, McKinnon PS, Levine DP, et al. Impact of empirical-therapy selection on outcomes of
intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococ-
cus aureus. Antimicrob Agents Chemother 2007; 51:3731–3733. - Tenover FC, Moellering RC. The rationale for revising the Clinical Laboratory Standards Institute
vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin
Infect Dis 2007; 44:1208–1215. - Skhirtladze K, Hutschla D, Fleck T, et al. Impaired target site penetration of vancomycin in diabetic
patients following cardiac surgery. Antimicrob Agents Chemother 2006; 50:1372–1375. - Moise PA, Sakoulas G, Forrest A, et al. Vancomycin in vitro bactericidal activity and its relationship
to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob
Agents Chemother 2007; 51:2582–2586. - Hidayat LK, Hsu DI, Quist R, et al. High- dose vancomycin therapy for methicillin-resistant
staphylococcus aureus infections; efficacy and toxicity, Arch Intern Med 2006; 166:2139–2144. - Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-
resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34:1481–1490. - Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by
methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis
2004; 38:521–528. - Jacquiline C, Batard E, Perez L, et al. In vivo efficacy of continuous infusion versus intermittent
dosing of linezolid compared to vancomycin in a methicillin- resistant Staphylococcus aureus rabbit
endocarditis model. Antimicrob Agents Chemother 2002; 46:3706–37011. - Sperber SJ, Levine JF, Gross PA. Persistent MRSA bacteremia in a patient with low Linezeloid
levels. Cin Infect Dis 2003; 36:675–676. - Colli A, Campodinico R, Gherli, T. Early switch from vancomycin to oral linezolid for treatment of
Gram-positive heart valve endocarditis. Ann Thorac Surg 2007; 84:87–91. - Sakoulas G, Eliopoulos GM, Alder J, et al. Efficacy of daptomycin in experimental endocarditis due
to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:1714–1718. - Jones T, Yeaman MR, Sakoulas G, et al. In failures in clinical treatment of Staphylococcus aureus
infection is daptomycin associated with alterations in surface charge, membrane phospholipid
asymmetry and drug binding. Antimicrob Agents Chemother 2018; 52:269–278. - Moise PA, Smyth DS, El-Fawal N, et al. Microbiological effects of prior vancomycin use in patients
with methicillin-resistant Staphylococcus aureus bacteremia. J Antimicrob Chemother 2008; 61:
85–90. - Cercenado E, Cercenado S, Gomez JA,et al. In vitro activity of tigecycline (GAR 936), a novel
glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished
susceptibility to glycolipids. J Antimicrob Chemother 2003; 52:138–139. - Walsh T, Pappas P, Winston DJ, et al. Voriconazole versus liposomal amphotericin B. for empirical
antifungal therapy. N Engl J Med 2002; 366:1745–1747. - Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of capsofungin amphotericin B. for invasive
candidiasis. N Engl J Med 2002; 347:2020–2029. - Anaisse EJ, Bishara AB, Solomkin JS. Fungal Infection. In: Souba WW, Fink MP, Jurkovich GJ, et al.,
eds. ACS Surgery 2005. New York: Web Professional Publishing, 2005:1486–1487. - Chan K-L, Tam J, Dumensil JG, et al. Effect of long-term has been used on embolic events infective
endocarditis. Clin Iinfect Dis 2008; 46:37–41. - Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines for the
American Heart Association: a guideline for the American Heart Association Rheumatic Fever,
Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young
and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and
258 Brusch